Approval of Lilly's obesity pill opens a new front in the weight-loss war

Eli Lilly's pill will compete in the booming, billion-dollar market for obesity medications against a rival from Novo Nordisk. The battle of the weight-loss pills begins now. Eli Lilly's once-daily weight reduction pill received approval from US drug authorities on April 1, 2026. This approval paves the way for a showdown with competitor Novo Nordisk, which has already been selling a tablet version of its drug Wegovy since the beginning of the year. Aiming for a $70 billion market The Wegovy pill reported one of the most successful product...